Polymer-Free Drug-Coated Coronary Stents in Patients with Stable Coronary Artery Disease at High Bleeding Risk.

Published

Journal Article (Review)

PURPOSE OF REVIEW: Patients with stable coronary artery disease (CAD) and a high risk of bleeding are not ideal candidates for a polymer-based drug-eluting stent (DES) because it requires 6-12 months of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI). The purpose of this review is to assess the angiographic and clinical outcomes of polymer-free drug-coated stents (PF-DCS) in stable CAD patients with a high bleeding risk. RECENT FINDINGS: Several randomized controlled trials (RCTs) have compared angiographic and clinical outcomes of PF-DCS with bare-metal stents (BMS), permanent polymer (PP)-DES, or biodegradable polymer (BP)-DES. However, none of these studies particularly recruited patients with stable CAD and a high risk of bleeding. Furthermore, there are limited data available on duration of DAPT following PF-DCS placement. PF-DCS has a better efficacy and similar safety as compared with BMS. PF-DCS with dual drug is noninferior to currently available PP-DES. Further RCTs are needed to assess the safety and efficacy of PF-DCS to BP-DES and PP-DES comparing shorter to standard durations of DAPT.

Full Text

Duke Authors

Cited Authors

  • Panchal, HB; Daggubati, R; Zhao, D; Rao, SV; Paul, T

Published Date

  • February 2017

Published In

Volume / Issue

  • 19 / 2

Start / End Page

  • 12 -

PubMed ID

  • 28185168

Pubmed Central ID

  • 28185168

Electronic International Standard Serial Number (EISSN)

  • 1534-3170

Digital Object Identifier (DOI)

  • 10.1007/s11886-017-0819-0

Language

  • eng

Conference Location

  • United States